구독하기
연구 모델
모델 라이브러리
연구용 마우스 모델
맞춤형 모델 제작
전임상 연구지원
완전 인간 항체 라이브러리
hCRBN/Rag2-KO(BALB/c) Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
hCRBN/Rag2-KO(BALB/c) Mouse
제품명
hCRBN/Rag2-KO(BALB/c) Mouse
제품 ID
C002136
품종 계통
BALB/cAnCya-Crbnem1(hCRBN)Rag2em1/Cya
Backgroud
BALB/cAnCya
상태
이 마우스 계통을 논문에서 사용할 경우, “hCRBN/Rag2-KO(BALB/c) Mouse (카탈로그 번호 C002136)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
Tumor Target Humanized Mouse ModelsImmune Target Humanized Mouse ModelsOther Immunodeficient Mice
ADC
AOC
Gene Editing Therapy
PROTAC & Molecular Glue
CDS Humanized Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
Tumor Target Humanized Mouse ModelsImmune Target Humanized Mouse ModelsOther Immunodeficient Mice
ADC
AOC
Gene Editing Therapy
PROTAC & Molecular Glue
CDS Humanized Models
기본 정보
관련 자료
기본 정보
유전자 별칭
Rag-2, MRT2, MRT2A
염색체
Chr 2, Chr 3
MGI ID
더보기
Datasheet
품종 계통 설명
The CRBN gene is located on human chromosome 3 and is broadly expressed across multiple tissues, with particularly prominent expression in brain tissue, kidney parenchyma, skeletal muscle, and various immune cell populations, including monocytes, macrophages, dendritic cells, and B lymphocytes [1]. The Cereblon protein encoded by this gene serves as a critical substrate recognition receptor of the CRL4-CRBN E3 ubiquitin ligase complex, playing an important regulatory role within cells. This complex specifically recognizes target proteins and mediates their ubiquitination, subsequently directing these proteins into the proteasomal degradation pathway, thereby precisely regulating multiple fundamental cellular processes, including protein homeostasis, ion channel transport activity, and AMPK signaling pathway transduction [1-2]. In the field of genetic disease research, it is well established that loss-of-function mutations in the CRBN gene are closely associated with the pathogenesis of non-syndromic intellectual disability with an autosomal recessive inheritance pattern [2]. Furthermore, as the primary molecular target of targeted protein degradation (TPD) therapy, the Cereblon protein can induce selective degradation of specific transcription factors by modulating the enzymatic activity of the CRL4-CRBN complex and altering its substrate recognition properties. This molecular mechanism has become an important theoretical foundation for the clinical treatment of malignant hematological diseases such as multiple myeloma, giving rise to various drug types, including molecular glues and proteolysis-targeting chimeras (PROTACs) [3-5].
The protein encoded by the RAG2 gene, together with the RAG1 protein, constitutes the RAG complex, which plays an essential role in V(D)J recombination during the maturation of B cells and T cells. During V(D)J recombination, the RAG complex attaches to recombination signal sequences (RSS) on the DNA, which are located adjacent to V, D, or J segments. The RAG complex cleaves the DNA between the signal sequences and the segments, enabling the segments to separate and move to different regions of the gene. This process is repeated multiple times in B cells and T cells, allowing V, D, and J segments to be arranged in different combinations. The resulting protein diversity provides a broader capability for recognizing foreign invaders and allows the body to effectively defend against infections. RAG2 not only participates in the catalysis of the reaction but also regulates the reaction by controlling access to specific genomic loci [6].
The hCRBN/Rag2-KO(BALB/c) mouse is a combined genetically modified model obtained by crossing hCRBN(BALB/c) mice (Catalog No.: C001724) with Rag2-KO(BALB/c) mice. The hCRBN/Rag2-KO(BALB/c) mouse can be used for screening, pharmacodynamic evaluation, safety evaluation, and mechanism of action studies of drugs targeting CRBN. Based on the Rag2 knockout background, this model is an immunodeficient mouse model with T and B cell deficiency, which can be used for broad research in various oncology and immunology fields, providing a preclinical research tool for exploring the role of CRBN-targeted intervention in the context of related diseases.
Reference
Barankiewicz J, Salomon-Perzyński A, Misiewicz-Krzemińska I, Lech-Marańda E. CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma. Cancers (Basel). 2022 Sep 16;14(18):4492.
Zhou L, Xu G. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases. J Mol Biol. 2022 Mar 15;434(5):167457.
An J, Zhang X. Crbn-based molecular Glues: Breakthroughs and perspectives. Bioorg Med Chem. 2024 Apr 15;104:117683.
Yamamoto J, Ito T, Yamaguchi Y, Handa H. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chem Soc Rev. 2022 Aug 1;51(15):6234-6250.
Thapa R, Bhat AA, Gupta G, Renuka Jyothi S, Kaur I, Kumar S, Sharma N, Prasad GVS, Pramanik A, Ali H. CRBN-PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications. Chem Biol Drug Des. 2024 Nov;104(5):e70009.
Schatz DG. V(D)J recombination. Immunol Rev. 2004 Aug;200:5-11.
변형 전략
The hCRBN/Rag2-KO(BALB/c) mouse is a genetically modified model generated by crossing hCRBN(BALB/c) mice (Catalog No.: C001724) with Rag2-KO(BALB/c) mice.

Figure 1. Gene editing strategy of hCRBN(BALB/c) mice. The exon 2 to partial intron 2 of mouse Crbn was replaced with Exon 2~11 of Human CRBN CDS-BGH pA cassette.

Figure 2. Gene editing strategy of Rag2-KO(BALB/c) mice. The mouse Rag2 gene is located on chromosome 2 and contains three exons. Both the start and stop codons are located on exon 3. The Rag2 gene knockout was achieved by targeting exon 3 using gene editing technology.
응용 분야
Screening, pharmacodynamic evaluation, safety evaluation, and mechanism-of-action studies of drugs targeting the CRBN protein;
Screening, development, and preclinical efficacy evaluation of CRBN-based targeted protein degradation (TPD) therapies;
Research on the pathological mechanisms and therapeutic approaches for non-syndromic intellectual disability;
Research on the pathological mechanisms and therapeutic approaches for malignant hematological diseases such as multiple myeloma.
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
